foxo4 dri senolytic human trial Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging FOXO4-DRI 10mg vial - Description
FOXO4 DRI 10mg vial Description RCpeptides FOXO4 DRI Vial 10mg Stemcode Peptides Buy FOXO4 DRI Peptide (Proxofim) 10mg BiotechPeptides The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Nature Communications Molecular modelling of the FOXO4 TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells ScienceDirect
Pay in 4 interest-free payments of $5.00 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5




